Meta-analyses of Adverse Effects Data Derived from Randomised
                    Controlled Trials as Compared to Observational Studies: Methodological
                    Overview by Golder, Su et al.
Meta-analyses of Adverse Effects Data Derived from
Randomised Controlled Trials as Compared to
Observational Studies: Methodological Overview
Su Golder
1*, Yoon K. Loke
2, Martin Bland
3
1Centre for Reviews and Dissemination, University of York, York, United Kingdom, 2School of Medicine, University of East Anglia, Norwich, United Kingdom,
3Department of Health Sciences, University of York, York, United Kingdom
Abstract
Background: There is considerable debate as to the relative merits of using randomised controlled trial (RCT) data as
opposed to observational data in systematic reviews of adverse effects. This meta-analysis of meta-analyses aimed to assess
the level of agreement or disagreement in the estimates of harm derived from meta-analysis of RCTs as compared to meta-
analysis of observational studies.
Methods and Findings: Searches were carried out in ten databases in addition to reference checking, contacting experts,
citation searches, and hand-searching key journals, conference proceedings, and Web sites. Studies were included where a
pooled relative measure of an adverse effect (odds ratio or risk ratio) from RCTs could be directly compared, using the ratio
of odds ratios, with the pooled estimate for the same adverse effect arising from observational studies. Nineteen studies,
yielding 58 meta-analyses, were identified for inclusion. The pooled ratio of odds ratios of RCTs compared to observational
studies was estimated to be 1.03 (95% confidence interval 0.93–1.15). There was less discrepancy with larger studies. The
symmetric funnel plot suggests that there is no consistent difference between risk estimates from meta-analysis of RCT data
and those from meta-analysis of observational studies. In almost all instances, the estimates of harm from meta-analyses of
the different study designs had 95% confidence intervals that overlapped (54/58, 93%). In terms of statistical significance, in
nearly two-thirds (37/58, 64%), the results agreed (both studies showing a significant increase or significant decrease or
both showing no significant difference). In only one meta-analysis about one adverse effect was there opposing statistical
significance.
Conclusions: Empirical evidence from this overview indicates that there is no difference on average in the risk estimate of
adverse effects of an intervention derived from meta-analyses of RCTs and meta-analyses of observational studies. This
suggests that systematic reviews of adverse effects should not be restricted to specific study types.
Please see later in the article for the Editors’ Summary.
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There is considerable debate regarding the relative utility of
different study designs in generating reliable quantitative estimates
for the risk of adverse effects. A diverse range of study designs
encompassing randomised controlled trials (RCTs) and non-
randomised studies (such as cohort or case-control studies) may
potentially record adverse effects of interventions and provide
useful data for systematic reviews and meta-analyses [1,2].
However, there are strengths and weaknesses inherent to each
study design, and different estimates and inferences about adverse
effects may arise depending on study type [3].
In theory, well-conducted RCTs yield unbiased estimates of
treatment effect, but there is often a distinct lack of RCT data on
adverse effects [2,4–7]. It is often impractical, too expensive, or
ethically difficult to investigate rare, long-term adverse effects with
RCTs [5,7–16]. Empirical studies have shown that many RCTs
fail to provide detailed adverse effects data, that the quality of
those that do report adverse effects is poor [6,17–31], and that the
reporting may be strongly influenced by expectations of investi-
gators and patients [32].
In general RCTs are designed and powered to explore efficacy
[1,3,9,30,33]. As the intended effects of treatment are more likely to
occur than adverse effects and to occur within the trial time frame,
RCTs may not be large enough, or have a sufficient follow-up to
identify rare, long-term adverse effects, or adverse effects that occur
after the drug has been discontinued [1–3,9,13,15,16,18,19,21,
26,30,33–53]. Moreover, generalisability of RCT data may be
limited if, as is often the case, trials specifically exclude patients at
high risk of adverse effects, such as children, the elderly, pregnant
women, patients with multiple comorbidities, and those with
potential drug interactions [1–3,15,38,39,41,45,46,54–56].
Given these limitations it may be important to evaluate the use of
data from non-randomised studies in systematic reviews of adverse
effects. Owing to the lack of randomisation, all types of observational
studies are potentially afflicted by an increased risk of bias (particularly
from confounding) [8,57] and may therefore be a much weaker study
design for establishing causation [12]. Nevertheless, observational study
designs may sometimes be the only available source of data for a
particular adverse effect, and are commonly used in evaluating adverse
effects [1,9,13,52,58,59]. It is also debatable how important it is to
control for confounding by indication for unanticipated adverse effects.
Authors have argued that confounding is less likely to occur when an
outcome is unintended or unanticipated than when the outcome is an
intended effect of the exposure. This is because the potential for that
adverse effect is not usually associated with the reasons for choosing a
particular treatment, and therefore does not influence the prescribing
decision [52,59–62]. For instance, in considering the risk of venous
thrombosis from oral contraceptives in healthy young women, the
choice of contraceptive may not be linked to risk factors for deep
venous thrombosis (an adverse effect that is not anticipated). Thus, any
d i f f e r e n c ei nr a t e so fv e n o u st h r o m b o s i sm a yb ed u et oad i f f e r e n c ei n
the risk of harm between contraceptives [52,62].
As both RCTs and observational studies are potentially valuable
sources of adverse effects data for meta-analysis, the extent of any
discrepancy between the pooled risk estimates from different study
designs is a key concern for systematic reviewers. Previous research
has tended to focus on differences in treatment effect between
RCTs and observational studies [63–69]. However, estimates of
beneficial effects may potentially be prone to different biases to
estimates of adverse effects amongst the different study designs.
Can the different study designs provide a consistent picture on the
risk of harm, or are the results from different study designs so
disparate that it would not be meaningful to combine them in a
single review? This uncertainty has not been fully addressed in
current methodological guidance on systematic reviews of harms
[46], probably because the existing research has so far been
inconclusive, with examples of both agreement and disagreement
in the reported risk of adverse effects between RCTs and
observational studies [1,11,15,48,51,70–78]. In this meta-analysis
of meta-analyses, we aimed to compare the estimates of harm (for
specific adverse effects) reported in meta-analysis of RCTs with
those reported in meta-analysis of observational studies for the
same adverse effect.
Methods
Search Strategy
Broad, non-specific searches were undertaken in ten electronic
databases to retrieve methodology papers related to any aspect of
the incorporation of adverse effects into systematic reviews. A list
of the databases and other sources searched is given in Text S1. In
addition, the bibliographies of any eligible articles identified were
checked for additional references, and citation searches were
carried out for all included references using ISI Web of
Knowledge. The search strategy used to identify relevant
methodological studies in the Cochrane Methodology Register is
described in full in Text S2. This strategy was translated as
appropriate for the other databases. No language restrictions were
applied to the search strategies. However, because of logistical
constraints, only non-English papers for which a translation was
readily available were retrieved.
Because of the limitations of searching for methodological
papers, it was envisaged that relevant papers may be missed by
searching databases alone. We therefore undertook hand-search-
ing of selected key journals, conference proceedings, and Web
sources, and made contact with other researchers in the field. In
particular, one reviewer (S. G.) undertook a detailed hand search
focusing on the Cochrane Database of Systematic Reviews and the
Database of Abstracts of Reviews of Effects (DARE) to identify
systematic reviews that had evaluated adverse effects as a primary
outcome. A second reviewer (Y. K. L.) checked the included and
excluded papers that arose from this hand search.
Inclusion Criteria
A meta-analysis or evaluation study was considered eligible for
inclusion in this review if it evaluated studies of more than one type
of design (for example, RCTs versus cohort or case-control studies)
on the identification and/or quantification of adverse effects of
health-care interventions. We were principally interested in meta-
analyses that reported pooled estimates of the risk of adverse
effects according to study designs that the authors stated as RCTs,
as opposed to analytic epidemiologic studies such as case-control
and controlled cohort studies (which authors may have lumped
together as a single ‘‘observational’’ category). Our review focuses
on the meta-analyses where it was possible to compare the pooled
risk ratios (RRs) or odds ratios (ORs) from RCTs against those
from other study designs.
Data Extraction
Information was collected on the primary objective of the meta-
analyses; the adverse effects, study designs, and interventions
included; the number of included studies and number of patients
by study design; the number of adverse effects in the treatment and
control arm or comparator group; and the type of outcome
statistic used in evaluating risk of harm.
We relied on the categorisation of study design as specified by
the authors of the meta-analysis. For example, if the author stated
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the studies were indeed RCTs and cohort studies.
Validity assessment and data extraction were carried out by one
reviewer (S. G.), and checked by a second reviewer (Y. K. L.). All
discrepancies were resolved after going back to the original source
papers, with full consensus reached after discussion.
Validity Assessment
The following criteria were used to consider the validity of
comparing risk estimates across different study designs. (1)
Presence of confounding factors: Discrepancies between the results
of RCTs and observational studies may arise because of factors
(e.g., differences in population, administration of intervention, or
outcome definition) other than study design. We recorded whether
the authors of the meta-analysis checked if the RCTs and
observational studies shared similar features in terms of popula-
tion, interventions, comparators, and measurement of outcomes
and whether they used methods such as restriction or stratification
by population, intervention, comparators, or outcomes to improve
the comparability of pooled risk estimates arising from different
groups of studies. (2) Heterogeneity by study design: We recorded
whether the authors of the meta-analysis explored heterogeneity of
the pooled studies by study design (using measures such as Chi
2 or
I
2). We assessed the extent of heterogeneity of each meta-analysis
using a cut-off point of p , 0.10 for Chi
2 test results, and we
specifically looked for instances where I
2 was reported as above
50%. In the few instances where both statistics were presented, the
results of I
2 were given precedence [79]. (3) Statistical analysis
comparing study designs: We recorded whether the authors of the
meta-analysis described the statistical methods by which the
magnitude of the difference between study designs was assessed.
Data Analysis
A descriptive summary of the data in terms of confidence interval
(CI) overlap between pooled sets of results by study design, and any
differences in the direction of effect between study designs, were
presented. The results were said to agree if both study designs
identified a significant increase, a significant decrease, or no
significant difference in the adverse effects under investigation.
Quantitative differences or discrepancies between the pooled
estimates from the respective study designs for each adverse effect
were illustrated by taking the ratio of odds ratios (ROR) from
meta-analysis of RCTs versus meta-analysis of observational
studies. We calculated ROR by using the pooled OR for the
adverse outcome from RCTs divided by the pooled OR for the
adverse outcome from observational studies. If the meta-analysis of
RCTs for a particular adverse effect yielded exactly the same OR
as the meta-analysis of observational studies (i.e., complete
agreement, or no discrepancy between study designs), then the
ROR would be 1.0 (and ln ROR=0). Because adverse events are
rare, ORs and RRs were treated as equivalent [80].
The estimated ROR from each ‘‘RCT versus observational
study’’ comparison was then used in a meta-analysis (random
effects inverse variance method; RevMan 5.0.25) to summarize the
overall ROR between RCTs and observational studies across all
the included reviews. The standard error (SE) of ROR can be
estimated using the SEs for the RCT and observational estimates:
SE(ROR) ~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE ln OR(RCT)
2z SE ln OR(Observ)
2
q
ð1Þ
SEs pertaining to each pooled OR(RCT) and OR(Observ) were
calculated from the published 95% CI.
Statistical heterogeneity was assessed using I
2 statistic, with I
2 values
of 30%–60% representing a moderate level of heterogeneity [81].
Results
Included Studies
In total, 52 articles were identified as potentially eligible for this
review. On further detailed evaluation, 33 of these articles either
compared different types of observational studies to one another
(for example, cohort studies versus case control studies) or
compared only the incidence of adverse effects (without reporting
the RR/OR) in those receiving the intervention according to type
of study [57,82–113].
We finally selected 19 eligible articles that compared the relative
risk or ORs from RCTs and observational studies (Figure 1)
[6,114–131]. These 19 articles covering meta-analysis of 58
separate adverse effects will be the focus of this paper. The 58
meta-analyses included a total of over 311 RCTs and over 222
observational studies (comprising 57 cohort studies, 75 case-
control studies, and at least 90 studies described as ‘‘observational’’
by the authors without specifying the exact type) (Table S1). (Exact
numbers of RCTs and observational studies cannot be calculated
as overlap in the included studies in McGettigan and Henry [127]
could not be ascertained.)
Two of the 19 articles were methodological evaluations with the
main aim of assessing the influence of study characteristics
(including study design) on the measurement of adverse effects
[6,127], whereas the remaining 17 were systematic reviews within
which subgroup analysis by study design was embedded [114–
126,128–131] (Table S1).
Adverse Effects
The majority of the articles compared the results from RCTs and
observational studies using only one adverse effect (11/19, 58%)
[114,115,117–119,121,122,124,125,129,130], whilst three included
one type of adverse effect (such as cancer, gastrointestinal
complications, or cardiovascular events) [116,127,128], and five
articles included a number of specified adverse effects (ranging from
two to nine effects) or any adverse effects [6,120,123,126,131].
Interventions
Most (17/19, 89%) of the articles included only one type of
intervention (such as hormone replacement therapy [HRT] or
nonsteroidal anti-inflammatory drugs) [114–120,122–131], whilst
one article looked at two interventions (HRT and oral contracep-
tives) [121] and another included nine interventions [6]. Most of
the analyses focused on the adverse effects of pharmacological
interventions; however, other topics assessed were surgical
interventions (such as bone marrow transplantation and hernia
operations) [6,120] and a diagnostic test (ultrasonography) [131].
Excluded Studies
Text S3 lists the 67 studies that were excluded from this
systematic review during the screening and data extraction phases,
with the reasons for exclusion.
Summary of Methodological Quality
Role of confounding factors. Although many of the meta-
analyses acknowledged the potential for confounding factors that
might yield discrepant findings between study designs, no
adjustment for confounding factors was reported in most instances
[6,114–116,118–122,124–126,128–131]. However, a few authors
did carry out subgroup analysis stratified for factors such as
population characteristics, drug dose, or duration of drug exposure.
Meta-analyses of Adverse Effects Data
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performed some adjustment for potential confounding factors: one
carried out meta-regression [123], and in the other methodological
evaluation the adjustment method carried out was unclear [127].
Heterogeneity by study design. Thirteen meta-analyses
measured the heterogeneity of at least one set of the included
studies grouped by study design using statistical analysis such as
Chi
2 or I
2 [6,115–117,119,121,123–125,127,129–131].
Figure 1. Flow chart for included studies.
doi:10.1371/journal.pmed.1001026.g001
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indication of heterogeneity; only five (15%) [6,117,130,131] of the
33 [6,115–117,119,121,123,124,129–131] sets of pooled RCTs
were significantly heterogeneous, and in two of these sets of RCTs
the heterogeneity was only moderate, with I
2=58.9% [117] and
I
2=58.8% [130].
Three of the four case-control studies, one of the four cohort
studies, and 14 of the 25 studies described as ‘‘observational
studies’’ also exhibited substantial heterogeneity.
Statistical analysis comparing study designs. Authors of
one meta-analysis explicitly tested for a difference between the
results of the different study designs [6]. Two other analyses
reported on the heterogeneity of the pooled RCTs, the pooled
observational studies, and the pooled RCTs and observational
studies, which can indicate statistical differences where the pooled
study designs combined are significantly heterogenous but no
significant heterogeneity is seen when the study designs are pooled
separately.
Data Analysis
Text S4 documents the decisions made in instances where the
same data were available in more than one format.
Size of studies. In ten methodological evaluations the total
number of participants was reported in each set of pooled studies by
study design [114,116,118–120,123,125,126,130,131], and in
another five methodological evaluations the pooled number of
participants was reported for at least one type of study design
[6,124,127–129]. Studies described as ‘‘observational’’ by the authors
contained the highest number of participants per study, 34,529
(3,798,154 participants/110 studies), followed by cohort studies,
33,613 (1,378,131 participants/41 studies). RCTs and case-control
studies had fewer participants, 2,228 (821,954 participants/369
studies) and 2,144 (105,067 participants/49 studies), respectively.
Confidence interval overlap. In almost all instances the CIs
for the pooled results from the different study designs overlapped
(Table 1). However, there were four pooled sets of results in three
methodological evaluations where the CIs did not overlap
[6,119,121].
Agreement and disagreement of results. In most of the
methodological evaluations the results of the treatment effect
agreed between types of study design [6,116,118,120,121,123–
131]. Most studies that showed agreement between study designs
did not find a significant increase or significant decrease in the
adverse effects under investigation (Table 1).
There were major discrepancies in one pooled set of results. Col
et al. [119] found an increase in breast cancer with menopausal
hormone therapy in RCTs but a decrease in observational studies.
There were other instances where although the direction of the
effect was not in opposing directions, apparently different
conclusions may have been reached had a review been restricted
to either RCTs or observational studies, and undue emphasis was
placed on statistical significance tests. For instance, a significant
increase in an adverse effect could be identified in an analysis of
RCT data, yet pooling the observational studies may have
identified no significant difference in adverse effects between the
treatment and control group. Table 1 shows that the most
common discrepancy between study types occurred when one set
of studies identified a significant increase whilst another study
design found no statistically significant difference. Given the
imprecision in deriving estimates of rare events, this may not
reflect any real difference between the estimates from RCTs and
observational studies, and it would be more sensible to concentrate
on the overlap of CIs rather than the variation in size of the p-
values from significance testing.
Ratio of risk ratio or odds ratios estimates. RRs or ORs
from the RCTs were compared to those from the observational
studies by meta-analysis of the respective ROR for each adverse
effect.
RCTs versus all ‘‘observational’’ studies. The overall
ROR from meta-analysis using the data from all the studies that
compared RCTs with either cohort studies or case-control studies,
or that grouped studies under the umbrella of ‘‘observational’’
studies was estimated to be 1.03 (95% CI 0.93–1.15) with
moderate heterogeneity (I
2=56%, 95% CI 38%–67%) (Figure 2).
In Figure 3 we plotted the magnitude of discrepancy (ROR)
from each meta-analysis against the precision of its estimates (1/
SE), with the contour lines showing the extent of statistical
Table 1. Confidence interval overlap and agreement between study designs.
Study Design
Comparisons
CIs
Overlapped Agreement in Findings between the Study Designs Discrepancy in Findings between the Study Designs
Both
Showed a
Significant
Increase
Both Did
Not
Identify
Any
Significant
Difference
Both
Showed a
Significant
Decrease
Total for
Any
Agreement
Significant
Risk
Increase in
One vs.
Significant
Risk
Decrease in
the Other
Significant
Increase In
One vs. No
Significant
Difference
in the
Other
Significant
Decrease in
One vs. No
Difference
in the
Other
Total for Any
Disagreement
RCTs vs. all ‘‘observational’’
studies (n=58)
54 (93%) 11 (19%) 23 (40%) 3 (5%) 37 (64%) 1 (2%) 19 (33%)
a 1 (2%) 21 (36%)
Subgroup analysis based on specific observational designs
RCTs vs. observational
studies (n=32)
29 (91%) 6 (19%) 13 (41%) 3 (9%) 22 (69%) 1 (3%) 8 (25%) 1 (3%) 10 (31%)
RCTs vs. cohort studies
(n=16)
16 (100%) 3 (19%) 8 (50%) 0 11 (69%) 0 5 (31%) 0 5 (31%)
RCTs vs. case-control
studies (n=10)
9 (90%) 2 (20%) 2 (20%) 0 4 (40% 0 6 (60%) 0 6 (60%)
aEight studies showed increased risk with RCTs; 11 studies showed increased risk with observational data.
doi:10.1371/journal.pmed.1001026.t001
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magnitude of discrepancy, with the central ln ROR of zero
indicating no discrepancy, or complete agreement between the
pooled OR estimated from RCTs and observational studies. The
y-axis illustrates the precision of the estimates (1/SE), with the data
points at the top end having greater precision. This symmetrical
distribution of the RORs of the various meta-analyses around the
central ln ROR value of zero illustrates that random variation may
be an important factor accounting for discrepant findings between
meta-analyses of RCTs versus observational studies. If there had
been any systematic and consistent bias that drove the results in a
particular direction for certain study designs, the plot of RORs
would likely be asymmetrical. The vertically tapering shape of the
funnel also suggests that the discrepancies between RCTs and
observational studies are less apparent when the estimates have
greater precision. This may support the need for larger studies to
assess adverse effects, whether they are RCTs or observational
studies.
Both figures can be interpreted as demonstrating that there are
no consistent systematic variations in pooled risk estimates of
adverse effects from RCTs versus observational studies.
Sensitivity analysis: limiting to one review per adverse
effect examined. There are no adverse effects for which two or
more separate meta-analyses have used exactly the same primary
studies (i.e., had complete overlap of RCTs and observational
studies) to generate the pooled estimates. This reflects the different
time periods, search strategies, and inclusion and exclusion criteria
that have been used by authors of these meta-analyses such that
even though they were looking at the same adverse effect, they
used data from different studies in generating pooled overall
estimates. As it turns out, the only adverse effect that was evaluated
in more than one review was venous thromboembolism (VTE).
There was some, but not complete, overlap of primary studies in
three separate reviews of VTE with HRT (involving three
overlapping case-control studies from a total of 18 observational
studies analysed) and two separate reviews of VTE with oral
Figure 3. Contour funnel plot: discrepancy (ln ROR) between study designs in relation to precision of estimates (1/SE).
doi:10.1371/journal.pmed.1001026.g003
Figure 2. Meta-analysis of RORs from RCTs versus all observational studies. Studies are listed by first author’s last name and year of
publication (Loke 2008 is [124]; AHRQ 2002 is [114]). In some studies more than one outcome or intervention was assessed. In these instances,
indicated by the lowercase letters after the study year, the data were entered in the meta-analysis separately. Other studies compared RCTs to cohort
studies and case-control studies separately and therefore are listed twice (with no lowercase letter after the study year).
doi:10.1371/journal.pmed.1001026.g002
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cohort studies, and two [of 20] overlapping case-control studies).
For the sensitivity analysis, we removed the three older meta-
analyses pertaining to VTE so that the modest overlap could be
further reduced, with only one review per specific adverse effect
for the sensitivity analysis. The most recent meta-analyses for VTE
(Canonico et al. [117] for VTE with HRT, Douketis et al. [121]
for VTE with oral contraceptives) were used for analysis of the
RORs. This yields RORs that are very similar to the original
estimates: 1.06 (95% CI 0.96–1.18) for the overall analysis RCTs
versus all observational studies, 1.00 (95% CI 0.71–1.42) for RCTs
versus case-control studies and 1.07 (95% CI 0.86–1.34) for RCTs
versus cohort studies.
Subgroup analysis. Subgroup analysis for comparison of
RCTs against specific types of ‘‘observational’’ studies was carried
out and is summarised in Table 2. Forest plots for each of these
comparisons can be viewed in Figure S1.
Discussion
Our analyses found little evidence of systematic differences in
adverse effect estimates obtained from meta-analysis of RCTs and
from meta-analysis of observational studies. Figure 3 shows that
discrepancies may arise not just from differences in study design or
systematic bias, but possibly because of the random variation,
fluctuations or noise, and imprecision in attempting to derive
estimates of rare events. There was less discrepancy between the
study designs in meta-analyses that generated more precise
estimates from larger studies, either because of better quality, or
because the populations were more similar (perhaps because large,
long-term RCTs capture a broad population similar to observa-
tional studies). Indeed, the adverse effects with discrepant results
between RCTs and observational studies were distributed
symmetrically to the right and left of the line of no difference,
meaning that neither study design consistently over- or underes-
timates risk of harm as compared to the other. It is likely that other
important factors such as population and delivery of intervention
are at play here—for instance, the major discrepancy identified in
Col et al. [119] for HRT and breast cancer is already well
documented. This discrepancy has also been explained by the
timing of the start of treatment relative to menopause, which was
different between trials and observational studies. After adjust-
ment, the results from the different study designs have been found
to no longer differ [132,133].
Most of the pooled results from the different study designs
concurred in terms of identifying a significant increase or decrease,
or no significant difference in risk of adverse effects. On the
occasions where a discrepancy was found, the difference usually
arose from a finding of no significant risk of adverse effects with
one study design, in contrast to a significant increase in adverse
effects from the other study design. This may reflect the limited
size of the included studies to identify significant differences in rare
adverse effects.
The increased risk in adverse effects in some studies was not
consistently related to any particular study design—RCTs found a
significant risk of adverse effects associated with the intervention
under investigation in eight instances, while observational studies
showed a significantly elevated risk in 11 cases.
Although reasons for discrepancies are unclear, specific factors
which may have led to differences in adverse effect estimates were
discussed by the respective authors. The differences between
observational studies and RCTs in McGettigan and Henry’s meta-
analysis of cardiovascular risk were thought to be attributable to
different dosages of anti-inflammatory drugs used [127]. Differ-
ences in Papanikolaou et al. [6] and Col et al. [119] were
attributed to differing study populations. Other methodological
evaluations discussed the nature of the study designs themselves
being a factor that may have led to differences in estimates. For
example, some stated that RCTs may record a higher incidence of
adverse effects because of closer monitoring of patients, longer
duration of treatment and follow-up, and more thorough
recording, in line with regulatory requirements [6,128]. Where
RCTs had a lower incidence of adverse effects, it was suggested
that this could be attributed to the exclusion of high-risk patients
[119] and possibly linked to support by manufacturers [6].
The overall ROR did not suggest any consistent differences in
adverse effects estimates from meta-analysis of RCTs versus meta-
analysis of observational studies. This interpretation is supported
by the funnel plot in Figure 3, which shows that differences
between the results of the two study designs are equally distributed
across the range. Some discrepancies may arise by chance, or
through lack of precision from limited sample size for detecting
rare adverse effects. While there are a few instances of sizeable
discrepancies, the pooled estimates in Figure 2 and Table 2
indicate that in the scheme of things (particularly where larger,
more precise primary studies are available), meta-analysis of
observational studies yield adverse effects estimates that broadly
match those from meta-analysis of RCTs.
Limitations
This systematic review of reviews and methodological evalua-
tions has a number of limitations. When comparing the pooled
results from different study designs it is important to consider any
confounding factors that may account for any differences
identified. For instance, if one set of studies was carried out on a
younger cohort of patients, with a lower drug dosage, or with
shorter duration of use, or relied on passive ascertainment of
adverse effects data [6,17,52,134], it might be expected that the
magnitude of any adverse effects recorded would be lower.
However, most of the methodological evaluations were not
conducted with the primary aim of assessing differences in study
design, but were systematic reviews with some secondary
comparative evaluation of study design embedded.
Another constraint of our overview is that we accepted
information and data as reported by the authors of the included
meta-analyses. We did not attempt to source the primary studies
Table 2. RORs from RCTs versus cohort studies, case-control studies, and studies described as ‘‘observational’’.
Study Design Comparison Pooled ROR (95% CI) Heterogeneity
RCTs versus cohort studies 1.02 (0.82–1.28) I
2=43%
RCTs versus case-control studies 0.84 (0.57–1.23) I
2=54%
RCTs versus studies described as ‘‘observational’’ 1.08 (0.94–1.22) I
2=60%
doi:10.1371/journal.pmed.1001026.t002
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extracting data from more than 550 papers. For instance, we relied
on the authors’ categorisation of study design but are aware that
authors may not all have used the same definitions. This is a
particular problem with observational studies, where it is often
difficult to determine the methodology used in the primary study
and categorise it appropriately. In order to overcome this
limitation, we chose to base our analysis on RCTs compared to
‘‘all’’ observational studies (either cohort studies, case-control
studies, or ‘‘observational’’ studies as defined by the author), with a
subgroup analysis based on different types of observational
designs.
Another important limitation to this review is the potentially
unrepresentative sample used. Systematic reviews with embedded
data comparing different study designs may have been missed.
The search strategy used was limited to a literature search to
identify methodological papers whose primary aim was to assess
the influence of study design on adverse effects and to a sift of the
full text of systematic reviews of adverse effects (as a primary
outcome) from the Cochrane Database of Systematic Reviews and
DARE. Nevertheless, it should be noted that the Cochrane
Database of Systematic Reviews and DARE databases cover a
large proportion of all systematic reviews and that systematic
reviews in which adverse effects are included as a secondary aim
are unlikely to present subgroup analysis by study design for the
adverse effects data.
There was considerable heterogeneity between the comparisons
of different studies, suggesting that any differences may be specific
to particular types of interventions or adverse effects. It may be
that particular types of adverse effects can be identified more easily
via particular types of study designs [3,14,135,136]. However, it
was difficult to assess the methodological evaluations by type of
adverse effects. This would be of interest, given that the literature
suggests that RCTs may be better at identifying some types of
adverse effects (such as common, anticipated, and short-term) than
observational studies.
Future Research
Where no randomized data exist, observational studies may be
the only recourse [137]. However, the potential value of
observational data needs to be further demonstrated, particularly
in specific situations where existing RCTs are short-term or based
on highly selected populations. Comparisons of risk estimates from
different types of observational studies (e.g., case-control as
opposed to cohort) merit further assessment.
In addition, it would be useful (based on a case-control type of
design) to carry out an in-depth examination of the meta-analyses
(and their included primary studies) with substantial discrepancy
amongst the RCTs and observational studies, as compared to
other meta-analyses where RCTs and observational studies had
close agreement. Any future research in this area should look into
the role of confounding factors (such as different population
selection and duration of drug exposure) between studies, and lack
of precision in point estimates of risk for rare events that could
have accounted for discrepant findings amongst RCTs and
observational studies.
Conclusions
Our findings have important implications for the conduct of
systematic reviews of harm, particularly with regards to selection
of a broad range of relevant studies. Although there are strengths
and weaknesses to each study design, empirical evidence from this
overview indicates that there is no difference on average between
estimates of the risk of adverse effects from meta-analyses of RCTs
and of observational studies. Instead of restricting the analysis to
certain study designs, it may be preferable for systematic reviewers
of adverse effects to evaluate a broad range of studies that can help
build a complete picture of any potential harm and improve the
generalisability of the review without loss of validity.
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Background. Whenever patients consult a doctor, they
expect the treatments they receive to be effective and to
have minimal adverse effects (side effects). To ensure that
this is the case, all treatments now undergo exhaustive
clinical research—carefully designed investigations that
test new treatments and therapies in people. Clinical
investigations fall into two main groups—randomized
controlled trials (RCTs) and observational, or non-
randomized, studies. In RCTs, groups of patients with a
specific disease or condition are randomly assigned to
receive the new treatment or a control treatment, and the
outcomes (for example, improvements in health and the
occurrence of specific adverse effects) of the two groups of
patients are compared. Because the patients are randomly
chosen, differences in outcomes between the two groups
are likely to be treatment-related. In observational studies,
patients who are receiving a specific treatment are enrolled
and outcomes in this group are compared to those in a
similar group of untreated patients. Because the patient
groups are not randomly chosen, differences in outcomes
between cases and controls may be the result of a hidden
shared characteristic among the cases rather than treatment-
related (so-called confounding variables).
Why Was This Study Done? Although data from
individual trials and studies are valuable, much more
information about a potential new treatment can be
obtained by systematically reviewing all the evidence and
then doing a meta-analysis (so-called evidence-based
medicine). A systematic review uses predefined criteria to
identify all the research on a treatment; meta-analysis is a
statistical method for combining the results of several
studies to yield ‘‘pooled estimates’’ of the treatment effect
(the efficacy of a treatment) and the risk of harm. Treatment
effect estimates can differ between RCTs and observational
studies, but what about adverse effect estimates? Can
different study designs provide a consistent picture of the
risk of harm, or are the results from different study designs so
disparate that it would be meaningless to combine them in a
single review? In this methodological overview, which
comprises a systematic review and meta-analyses, the
researchers assess the level of agreement in the estimates
of harm derived from meta-analysis of RCTs with estimates
derived from meta-analysis of observational studies.
What Did the Researchers Do and Find? The researchers
searched literature databases and reference lists, consulted
experts, and hand-searched various other sources for studies
in which the pooled estimate of an adverse effect from RCTs
could be directly compared to the pooled estimate for the
same adverse effect from observational studies. They
identified 19 studies that together covered 58 separate
adverse effects. In almost all instances, the estimates of harm
obtained from meta-analyses of RCTs and observational
studies had overlapping 95% confidence intervals. That is,
in statistical terms, the estimates of harm were similar.
Moreover, in nearly two-thirds of cases, there was agreement
between RCTs and observational studies about whether a
treatment caused a significant increase in adverse effects, a
significant decrease, or no significant change (a significant
change is one unlikely to have occurred by chance). Finally,
the researchers used meta-analysis to calculate that the
pooled ratio of the odds ratios (a statistical measurement of
risk) of RCTs compared to observational studies was 1.03.
This figure suggests that there was no consistent difference
between risk estimates obtained from meta-analysis of RCT
data and those obtained from meta-analysis of observational
study data.
What Do These Findings Mean? The findings of this
methodological overview suggest that there is no difference
on average in the risk estimate of an intervention’s adverse
effects obtained from meta-analyses of RCTs and from meta-
analyses of observational studies. Although limited by some
aspects of its design, this overview has several important
implications for the conduct of systematic reviews of adverse
effects. In particular, it suggests that, rather than limiting
systematic reviews to certain study designs, it might be
better to evaluate a broad range of studies. In this way, it
might be possible to build a more complete, more
generalizable picture of potential harms associated with an
intervention, without any loss of validity, than by evaluating
a single type of study. Such a picture, in combination with
estimates of treatment effects also obtained from systematic
reviews and meta-analyses, would help clinicians decide the
best treatment for their patients.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001026.
N The US National Institutes of Health provide information
on clinical research; the UK National Health Service Choices
Web site also has a page on clinical trials and medical
research
N The Cochrane Collaboration produces and disseminates
systematic reviews of health-care interventions
N Medline Plus provides links to further information about
clinical trials (in English and Spanish)
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